Fluorescent PARP Inhibitors Applied To Intracranial Glioblastoma: Accumulation and Persistence In Vivo.

Rucaparib-containing fluorescent probes ( 1 - 3 ) inhibit PARP1 in cell models. One of these ( 1 ) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.